Fighting Cancer
with a Novel Oncolytic
Virus Platform

Fighting Cancer
with a Novel Oncolytic
Virus Platform

Phase1/2 Results

In a Phase 1/2 clinical trial on brain cancer patients (Glioblastoma), four of twelve terminal patients responded to treatment and one went into complete remission!

Our Vision

Develop breakthrough, targeted anti-cancer viral products that will either treat morbid diseases or transform them into chronic, manageable ones.

Our Vision

Develop breakthrough, targeted anti-cancer viral products that will either treat morbid diseases or transform them into chronic, manageable ones.

NADAV Technology

We are pursuing the development of innovative viral products to fight diverse cancers based on a proprietary virus-based technology platform, NADAV.

NADAV Technology

We are pursuing the development of innovative viral products to fight diverse cancers based on a proprietary virus-based technology platform, NADAV.

Our Products

ViruCure is developing a novel biological pharmaceutical platform (NADAV) for targeted treatment of diverse cancers.